On July 7, 2021 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, reported that the company will present at Access to Giving Virtual Conference (Press release, Panbela Therapeutics, JUL 7, 2021, View Source [SID1234584688]). The presentation will be given by Panbela’s President & Chief Executive Officer, Jennifer K. Simpson, PhD, MSN, CRNP.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Registration Details
Date: Thusday, July 15, 2021
Time: 10:30 a.m. ET
Link: https://access-to-giving.events.issuerdirect.com/signup
To learn more about the event or to schedule a one-on-one meeting with Panbela management, please visit View Source or email [email protected].
About Access to Giving Virtual Conference
Access to Giving is a first-of-its-kind virtual investor conference where companies from microcap all the way up to megacap will have the opportunity to present their story and conduct 1×1 meetings with qualified investors, for charity. Investors will make donations to purchase a block of meetings to meet with companies.
About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting potential complementary activity with an existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Recently observed serious visual adverse events are being evaluated and patients with a history of retinopathy or at risk of retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the current Panbela sponsored clinical trial provides support for continued evaluation of SBP-101 in a randomized clinical trial. For more information, please visit View Source